Press releases, new investments, exits, and perspectives on the European HealthTech investment landscape from the Hygeia Ventures team.
Fund I launches its pre-marketing phase with a €100M target, Luxembourg RAIF structure, AIFMD compliance and SFDR Article 8 classification. First close targeted for Q4 2026.
Christos Vaitsis on why EU life sciences VC captures just 7% of the global market despite world-class science — and what it takes to build a bridge from public grant capital to institutional venture capital.
Per Horn on the rationale behind Hygeia's entry point — after scientific validation, after grant-based non-dilutive funding, and before institutional scale capital.
Per Horn and Christos Vaitsis bring combined 30+ years of European HealthTech experience as GPs of the new Fund I — with a Senior Venture Partner appointment to follow.
More articles will appear here as Fund I progresses through first close and begins deploying capital.